Chlorprothixene

Chlorprothixene (Cloxan, Taractan, Truxal) is a typical antipsychotic drug of the thioxanthene class and was the first of the series to be synthesized. It was introduced in 1959 by Lundbeck.

Chlorprothixene is not approved for use in the United States.

Pharmacology

Chlorprothixene exerts strong antagonism at the following receptors:

Chlorprothixene does also act as FIASMA (functional inhibitor of acid sphingomyelinase).

One metabolite of chlorprothixene is N-demethylchlorprothixene.

Indications

Chlorprothixene's principal indications are the treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occurring as part of bipolar disorders.